Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female individual 2-45 years of age~2. Participants/Parents who have voluntarily given informed consent and/or assent.~3. Participants/Parents willing to commit complying with the study procedures of the investigator and available for the entire duration of study~Exclusion Criteria:~1. Participants concomitantly enrolled or scheduled to be enrolled in another trial~2. Acute illness, in particular infectious diseases or fever (axillary temperature \> 38°C), with in three days prior to enrollment and vaccination.~3. Known history of allergy to vaccines or other medications~4. Known history of allergy to egg, chiken protein, neomycin and formaldehyde.~5. History of uncontrolled coagulopathy or blood disorders~6. Known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (\> 20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs~7. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives~8. Pregnancy \& Lactation (female adults)~9. Female with child-bearing potential during the study period. i.e., sexually active and not practicing effective acceptable contraceptive method~10. Individuals who have previously received any vaccines against typhoid fever~11. Individuals already immunized with any licensed vaccine within 4 weeks prior to enrolment/vaccination (day 0) and expected to receive other licensed vaccines within 60 days following the first dose (day 0), except for tetanus toxoid vaccine~12. Individuals who have a previously ascertained or suspected disease caused by S. typhi.~13. Individuals who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. typhi~14. History of alcohol or substance abuse~15. Subject planning to move from the study area before the end of study period

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Test group (Type: EXPERIMENTAL): Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
- Comparator group (Type: ACTIVE_COMPARATOR): Biological/Vaccine:~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28).

Based on this trial design, predict the completion outcome and termination type (if applicable).